K-numberK250342
Device namePowder-Free Polychloroprene Examination Glove (Green Color) Tested for Use with Chemotherapy Drugs and Fentanyl
ApplicantEncompass Industries Sdn. Bhd.
Product codeLZA
Device classClass I
Decision dateJul 8, 2025
DecisionSubstantially Equivalent
Regulation880.6250
AI Summary extracted from FDA summary PDF · never regenerated
Intended use

This is a powder-free, non-sterile polychloroprene examination glove in green color intended for medical purposes to prevent contamination between patient and examiner. The glove has been tested for permeation resistance to 12 chemotherapy drugs (including Cisplatin, Paclitaxel, and Methotrexate) and Fentanyl citrate using ASTM D6978, with breakthrough times of >240 minutes for most drugs tested.

Technological characteristics

The proposed device is made of polychloroprene (same material as predicate), is powder-free and non-sterile, available in sizes XS through XXL, and meets ASTM D6977-19 for dimensions and physical properties. The only technological difference is color (green vs. blue in predicate), supported by biocompatibility testing showing equivalent skin irritation, sensitization, and toxicity profiles across different colors.

Test standards cited

ASTM D6977-19 (dimensions, physical properties, powder residual), ASTM D5151-19 (freedom from holes), ASTM D412 and D573 (tensile strength and elongation before/after aging), ASTM D6124-06 (residual powder), ASTM D6978-05 (chemotherapy drug permeation), ISO 10993-10 (skin irritation and sensitization), ISO 10993-11 (acute systemic toxicity), and 21 CFR 800.20 (pinhole defects).

Substantial equivalence argument

The proposed device is substantially equivalent to the predicate (K212148, polychloroprene glove tested for chemotherapy drugs) because it is identical in material, construction, intended use, and regulatory classification. Both devices demonstrate equivalent performance across all critical safety and effectiveness parameters: dimensional requirements, physical properties, freedom from holes, biocompatibility, and chemotherapy drug permeation. The color difference (green vs. blue) is a minor cosmetic variation supported by identical biocompatibility results, and the addition of Fentanyl testing extends the predicate's chemotherapy claims without introducing new safety concerns, as >240 min breakthrough time exceeds clinical use duration.

Extracted by AI from the official FDA summary PDF →
Source

View the full FDA submission: accessdata.fda.gov

Researching this as a predicate?
Want a transparent AI-ranking score, AI-discovered related predicates, ongoing safety and warning-letter monitoring, full predicate chain lineage, and a drafted SE rationale — all saved to your own project? That's what an account adds.
Start free trial →

Everything you need for a 510(k) submission. Nothing you don't.

14-day free trial. No setup. Cancel anytime.

Start free trial →
Building an AI or ML-enabled device? Predicate search, PCCP tracking, and AI-specific FDA intelligence — built exclusively for AI/ML devices. Try AIFDA Intel →